While 5-HT3 RAs are advised for the first-line prevention of CINV, the medical literature has expressed concerns regarding adverse events (AEs) such as headaches, constipation, elevated ALT, and prolongation of the QT interval, which is linked to severe ventricular arrhythmias (Schwartzberg et al., 2014; Tricco et al., 2016). The gene discussed is GPT; the disease is Ventricular arrhythmia.